Bain Capital
Bain Capital is a Boston-based multi-asset alternative investment firm that sources, funds, and manages investments across private equity, venture capital, credit, and public equity. Founded in 1984, it operates globally with specialized units focused on growth and buyout investments, life sciences, and impact-oriented opportunities. The firm backs companies across sectors including healthcare and life sciences, technology, software and data services, financial services, consumer, manufacturing, and industrials, spanning from early-stage ventures to growth equity and large-scale acquisitions. It emphasizes value creation through strategic support and partnerships, leveraging deep operating experience and a global network. Its life sciences arm targets pharmaceutical, biotechnology, medical device, and diagnostic companies; the Double Impact unit pursues market-rate returns alongside measurable social and environmental benefits; Bain Capital Ventures backs technology-enabled businesses from seed to growth across enterprise software, infrastructure, and services. The firm maintains offices in Boston and major markets worldwide, aiming to deliver competitive returns while supporting innovation and economic development.
Jennifer Davis
Partner, Private Equity, Consumer and Retail Vertical and Member of the North American Private Equity Team
Liraz Evenor
Managing Director Private Equity and Director in the Consumer and Retail Vertical & Member of the Portfolio Group for North America Private Equity
Alison Holmes
Principal, Private Equity and Consumer, Retail and Dining Vertical & Member of the North American Private Equity Team
Andrew Kaplan
Partner, Private Equity and Healthcare Vertical and Member Of The North American Private Equity Team
Christopher Kastner
Managing Director, Portfolio Group and Member of the North American Private Equity team
Phillip Loughlin
Partner, Global Head of the Financial and Business Services Vertical and Member of the Consumer / Retail Vertical
James Mackey
Principal, Private Equity and Technology Vertical and Member of the North American Private Equity Team
Giacomo Massetti
Managing Director, Consumer and Industrial Verticals and Member of the European Private Equity team
Cara Nealon
Senior Vice President, Portfolio Group and Member of the North American Private Equity Team
Radhika Subramanian
Principal, Consumer, Retail and Financial services and a Member of the Asia Pacific Private Equity team
Past deals in Eastern US
Lincoln Financial Group
Post in 2025
Founded in 1905, Lincoln Financial Group is a Fortune 500 company offering a diverse range of financial services and solutions, including investments, asset management, mutual funds, annuities, alternative investments, brokerage solutions, life insurance, retirement planning, and group benefits.
HealthEdge Software
Acquisition in 2025
HealthEdge provides a modern suite of products, HealthRules, built on patented technology. It enables healthcare payors to innovate, reduce costs, and improve outcomes by connecting everyone in the healthcare delivery cycle.
Solid Biosciences
Post in 2025
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.
Abcuro
Series C in 2025
Abcuro develops immunotherapies targeting autoimmunity and cancer. Founded in 2015, the company uses bioinformatics and ex-vivo validation to uncover novel immune system targets.
Cofactr
Series A in 2024
Cofactr specializes in end-to-end supply chain automation for critical industries such as aerospace, defense, medtech, and robotics. Established in New York in 2021, the company helps these sectors optimize procurement and logistics to deliver mission-critical hardware.
CereVasc
Series B in 2024
CereVasc, Inc. is a medical device company based in Auburndale, Massachusetts, specializing in the development of innovative, minimally invasive treatments for neurological diseases. The company has created the eShunt System, an endovascularly deliverable cerebrospinal fluid (CSF) shunt designed to replace traditional surgical methods for treating communicating hydrocephalus. This system aims to eliminate the need for invasive surgery, general anesthesia, and hospitalization, which are typically associated with the conventional use of ventriculo-peritoneal shunts. By providing a less invasive alternative, CereVasc seeks to improve patient outcomes and reduce the overall costs related to the surgical management of life-threatening neurological conditions. Established in 2014, CereVasc is focused on advancing healthcare solutions that enhance the treatment of various neurological brain disorders.
Century Therapeutics
Post in 2024
Century Therapeutics is a biotechnology company developing allogeneic cell therapies derived from induced pluripotent stem cells to treat cancer and related diseases. Its platform enables engineering of iPSCs into NK and T cells with master cell banks of modified cells that can be expanded and differentiated into standardized, off-the-shelf therapies. The company combines CRISPR-mediated gene editing, proprietary chimeric antigen receptors, Allo-Evasion technology, and manufacturing capabilities to enable scalable production of homogeneous cell products for hematologic and solid tumors. While focused on oncology, its platform also targets autoimmune and inflammatory diseases with the goal of improving cell therapy performance and reducing host immune rejection.
Xilio Therapeutics
Post in 2024
Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.
Areteia Therapeutics
Series A in 2024
Areteia Therapeutics is a biotechnology company focused on developing oral therapies for eosinophilic asthma to improve disease control. The company was spun out of Knopp and is advancing an oral drug designed to inhibit eosinophil maturation, aiming to reduce inflammation and alleviate symptoms of severe asthma. Phase 2 data from its program indicated the oral candidate lowers blood eosinophil counts, a marker associated with better lung function. By pursuing an oral, non-injectable treatment option, Areteia seeks to offer a convenient alternative to injectable therapies and broaden access for asthma patients. The company’s work centers on targeting eosinophil-related pathways to enhance asthma management and patient quality of life.
Solid Biosciences
Post in 2024
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.
Nimbus Therapeutics
Private Equity Round in 2023
Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.
Cofactr
Funding Round in 2023
Cofactr specializes in end-to-end supply chain automation for critical industries such as aerospace, defense, medtech, and robotics. Established in New York in 2021, the company helps these sectors optimize procurement and logistics to deliver mission-critical hardware.
Alkeus Pharmaceuticals
Series B in 2023
Alkeus Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston that specializes in developing treatments for serious ophthalmic conditions. The company's primary focus is on addressing untreatable diseases of the eye, with its lead drug candidate being an orally delivered compound aimed at treating Stargardt disease and age-related macular degeneration. Through its innovative approach, Alkeus aims to empower medical professionals to manage symptoms of irreversible vision loss at an earlier stage in affected patients.
Disc Medicine
Post in 2023
Disc Medicine is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with severe hematologic disorders. Its pipeline includes therapies targeting erythropoietic porphyrias, Diamond-Blackfan Anemia, anemia of myelofibrosis and chronic kidney disease, as well as polycythemia vera.
Jnana Therapeutics
Series C in 2022
Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.
Oort
Seed Round in 2022
Oort is an identity threat detection and response platform focused on enhancing enterprise security. Recognizing that over 60% of security breaches involve the abuse of valid identity credentials, Oort positions identity as a critical aspect of cybersecurity. The company offers a Software as a Service (SaaS) platform that allows cybersecurity and IT professionals to efficiently manage their identity and access management (IAM) programs. With a quick deployment process and a focus on reducing identity vulnerabilities at scale, Oort provides organizations with enhanced visibility and control over their identity attack surface. It operates as a fully remote startup based in Boston, MA, and its innovative solutions help clients secure their digital supply chains. Oort is supported by prominent investors and aims to equip security teams with the tools needed to combat identity threats effectively.
Oort
Series A in 2022
Oort is an identity threat detection and response platform focused on enhancing enterprise security. Recognizing that over 60% of security breaches involve the abuse of valid identity credentials, Oort positions identity as a critical aspect of cybersecurity. The company offers a Software as a Service (SaaS) platform that allows cybersecurity and IT professionals to efficiently manage their identity and access management (IAM) programs. With a quick deployment process and a focus on reducing identity vulnerabilities at scale, Oort provides organizations with enhanced visibility and control over their identity attack surface. It operates as a fully remote startup based in Boston, MA, and its innovative solutions help clients secure their digital supply chains. Oort is supported by prominent investors and aims to equip security teams with the tools needed to combat identity threats effectively.
Solid Biosciences
Post in 2022
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.
Nimbus Therapeutics
Venture Round in 2022
Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.
Areteia Therapeutics
Series A in 2022
Areteia Therapeutics is a biotechnology company focused on developing oral therapies for eosinophilic asthma to improve disease control. The company was spun out of Knopp and is advancing an oral drug designed to inhibit eosinophil maturation, aiming to reduce inflammation and alleviate symptoms of severe asthma. Phase 2 data from its program indicated the oral candidate lowers blood eosinophil counts, a marker associated with better lung function. By pursuing an oral, non-injectable treatment option, Areteia seeks to offer a convenient alternative to injectable therapies and broaden access for asthma patients. The company’s work centers on targeting eosinophil-related pathways to enhance asthma management and patient quality of life.
X4 Pharmaceuticals
Post in 2022
X4 Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapeutics targeting chemokine receptor CXCR4. Its lead drug candidate, mavorixafor (X4P-001), is in Phase III trials for the treatment of WHIM syndrome and has shown promising results in other indications such as severe congenital neutropenia and clear cell renal cell carcinoma.
Grid.ai
Series B in 2022
Grid.ai, Inc. is a technology company founded in 2019 and based in New York, New York, that specializes in developing a platform for training artificial intelligence models using cloud-based graphics processing units (GPUs) and tensor processing units (TPUs). The platform provides several tools, including Grid Train, which facilitates research iteration and simplifies AI research, as well as Grid View, a web application for monitoring and managing infrastructure. Additionally, it offers Tensorboard for analyzing experiments. The company's solutions are designed to enhance the capabilities of machine learning engineers, data scientists, and AI researchers, allowing them to build advanced AI models and applications with minimal changes to existing code. Grid.ai emerged from the creators of the widely used PyTorch Lightning framework, further solidifying its expertise in high-performance AI research.
HYCU
Series B in 2022
HYCU is a leading provider of multi-cloud data protection as a service, specializing in data backup and recovery solutions for on-premises, cloud-native, and SaaS environments. The company's innovative R-Cloud platform delivers effective data protection, migration, disaster recovery, and ransomware protection, simplifying the process for thousands of organizations globally. By eliminating the complexities and costs associated with traditional data protection solutions, HYCU has established itself as a top choice in the SaaS data protection industry. The company is based in Boston, Massachusetts, and has achieved a notable Net Promoter Score reflecting high customer satisfaction. To date, HYCU has raised significant venture capital funding to support its growth and development in the competitive data management market.
Cofactr
Seed Round in 2022
Cofactr specializes in end-to-end supply chain automation for critical industries such as aerospace, defense, medtech, and robotics. Established in New York in 2021, the company helps these sectors optimize procurement and logistics to deliver mission-critical hardware.
Fidel API
Series B in 2022
Fidel API is a financial infrastructure platform that allows developers to create programmable experiences during transaction events on payment cards. Established in 2018 and headquartered in London, with additional offices in Lisbon and New York, Fidel API provides tools that enhance interactions between merchants and consumers by facilitating real-time, event-driven engagements. The platform is designed to integrate seamlessly with major payment networks, such as Visa and Mastercard, to deliver detailed transaction data, including amount, location, date, and merchant. This capability supports improved marketing strategies and customer engagement through tailored loyalty and rewards programs, as well as streamlined processes for reimbursements and expense management. The company serves a diverse clientele, ranging from startups to large enterprises, and has established partnerships with prominent firms across various sectors.
FreeWill
Series B in 2022
FreeWill Co. is a New York-based company that develops and operates an online estate planning platform. The service offers users access to legal forms and information, simplifying the process of estate planning and facilitating charitable donations. By providing free and user-friendly tools, FreeWill enables donors and fundraisers to make tax-advantaged gifts more easily, streamlining the process of making bequests and donations. The company's mission centers on addressing estate planning needs while promoting philanthropic efforts, ultimately making it simpler for individuals to contribute to charitable organizations.
Hometap
Venture Round in 2021
Hometap, founded in 2018 and based in Boston, Massachusetts, is a fintech company that specializes in home equity investments. It allows homeowners to access funds immediately without taking on loans or selling their homes. Homeowners can use these funds for various purposes such as paying off debt or making renovations, all while avoiding added debt or monthly payments. Hometap provides this cash in exchange for a percentage of the future appreciation of the home's value.
Bain Capital
Acquisition in 2021
Bain Capital is a Boston-based multi-asset alternative investment firm that sources, funds, and manages investments across private equity, venture capital, credit, and public equity. Founded in 1984, it operates globally with specialized units focused on growth and buyout investments, life sciences, and impact-oriented opportunities. The firm backs companies across sectors including healthcare and life sciences, technology, software and data services, financial services, consumer, manufacturing, and industrials, spanning from early-stage ventures to growth equity and large-scale acquisitions. It emphasizes value creation through strategic support and partnerships, leveraging deep operating experience and a global network. Its life sciences arm targets pharmaceutical, biotechnology, medical device, and diagnostic companies; the Double Impact unit pursues market-rate returns alongside measurable social and environmental benefits; Bain Capital Ventures backs technology-enabled businesses from seed to growth across enterprise software, infrastructure, and services. The firm maintains offices in Boston and major markets worldwide, aiming to deliver competitive returns while supporting innovation and economic development.
Socure
Series E in 2021
Socure develops digital identity verification solutions using artificial intelligence and machine learning. Its platform authenticates identities in real-time from various online/offline sources, automating customer identification program (CIP), know your customer (KYC), and anti-money laundering (AML) compliance initiatives.
Cardurion Pharmaceuticals
Venture Round in 2021
Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.
Centivo
Venture Round in 2021
Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.
Ginkgo Bioworks
Post in 2021
Founded in 2008, Ginkgo Bioworks designs, engineers, and licenses organisms for various applications. It discovers molecules for flavors, sweeteners, cosmetics, crops, pharmaceuticals, and generates probiotic bacteria for health benefits. The company serves markets such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.
ConvenientMD
Private Equity Round in 2021
ConvenientMD LLC is an urgent care provider that specializes in treating non-life-threatening injuries and illnesses. Founded in 2011 and based in Portsmouth, New Hampshire, the company offers a range of services including treatment for sprains, strains, fractures, cuts, colds, bronchitis, and various infections. Additionally, ConvenientMD provides preventive care such as physicals, immunizations, and on-site prescriptions, along with X-ray and laboratory services. Patients can access care without an appointment, with centers open daily from 8 am to 8 pm, ensuring prompt service with minimal wait times. The company operates multiple locations across New Hampshire, Maine, and Massachusetts, emphasizing high-quality medical care delivered by a professional team using advanced medical equipment.
Cerevel Therapeutics
Post in 2021
Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company is advancing a diverse pipeline that includes five clinical-stage investigational therapies and several preclinical compounds targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Key products under development include CVL-231, a positive allosteric modulator for schizophrenia; CVL-865, which is being tested for drug-resistant focal onset epilepsy and acute anxiety; and Tavapadon, a selective dopamine D1/D5 partial agonist for Parkinson's disease. Cerevel Therapeutics employs a unique approach that leverages expertise in neurocircuitry and receptor selectivity to address unmet medical needs in the field of neuroscience.
Hand In Hand Soap
Funding Round in 2021
Hand In Hand Soap, founded in 2011 by Bill Glaab and Courtney Apple, is a personal care brand based in Wynnewood, Pennsylvania. The company specializes in a range of products including bar soap, liquid hand soap, hand sanitizer, body wash, sugar scrubs, and lotions. Committed to social responsibility, Hand In Hand operates a Give Back program, donating a bar of soap and access to clean water for every product sold, resulting in over 13 million bars of soap and significant contributions to water access for children in need. Additionally, the company prioritizes sustainability by producing palm oil-free products and actively educating consumers about the environmental and human rights issues associated with palm oil production.
Harry's
Series E in 2021
Founded in 2012, Harry's is a New York-based company that manufactures and sells high-quality shaving products. Its product range includes razors, shaving creams, grooming kits, and face care products, available both individually and through a subscription service.
HYCU
Series A in 2021
HYCU is a leading provider of multi-cloud data protection as a service, specializing in data backup and recovery solutions for on-premises, cloud-native, and SaaS environments. The company's innovative R-Cloud platform delivers effective data protection, migration, disaster recovery, and ransomware protection, simplifying the process for thousands of organizations globally. By eliminating the complexities and costs associated with traditional data protection solutions, HYCU has established itself as a top choice in the SaaS data protection industry. The company is based in Boston, Massachusetts, and has achieved a notable Net Promoter Score reflecting high customer satisfaction. To date, HYCU has raised significant venture capital funding to support its growth and development in the competitive data management market.
X4 Pharmaceuticals
Post in 2021
X4 Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapeutics targeting chemokine receptor CXCR4. Its lead drug candidate, mavorixafor (X4P-001), is in Phase III trials for the treatment of WHIM syndrome and has shown promising results in other indications such as severe congenital neutropenia and clear cell renal cell carcinoma.
Hi Marley
Series B in 2021
Hi Marley is a conversation platform for the insurance industry that combines intelligent messaging with human support to connect customers with insurers. The platform enables insurers to engage policyholders through messaging via its Marley web application, facilitating updates and responses to routine questions. It supports auto, home, and business lines and emphasizes real-time coaching, multilingual support, and automated workflows to enhance customer engagement and operational efficiency. Founded in 2017 and based in Boston, Massachusetts, the company targets insurers seeking to streamline communications and improve satisfaction through a shared messaging experience.
Xilio Therapeutics
Series C in 2021
Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.
River 3 Renal
Series A in 2021
River 3 Renal is a developer of novel therapies designed to target orphan diseases in the renal space.
The company's technology has the potential to address the unmet need in several kidney diseases, by further improving the standard of care, enabling medical practitioners to treat patients in a better way.
River 3 Renal was established in 2020 in New York, USA.
TeachTown
Private Equity Round in 2021
TeachTown Inc. develops education solutions for students with autism spectrum disorder and other developmental and emotional/behavioral disorders. It offers TeachTown Basics, a computer-delivered and teacher-led ABA instruction program to improve vocabulary, listening, social-emotional development, independence, academics, and cognitive skills, and TeachTown Social Skills, an online social skills curriculum and assessment that uses character-based video modeling for elementary and middle school students. The company provides professional development for teachers, paraprofessionals, specialists, and administrators, and serves schools, children, and families through its online store.
EQRx
Series B in 2021
EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.
Solid Biosciences
Post in 2020
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.
OpenFin
Venture Round in 2020
OpenFin provides runtime technology solutions for financial desktops. Its platform enables web applications to run outside the browser, generating real-time notifications, communicating with other applications, and meeting strict security standards. Serving financial services industries globally.
Centivo
Series B in 2020
Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.
Grid.ai
Series A in 2020
Grid.ai, Inc. is a technology company founded in 2019 and based in New York, New York, that specializes in developing a platform for training artificial intelligence models using cloud-based graphics processing units (GPUs) and tensor processing units (TPUs). The platform provides several tools, including Grid Train, which facilitates research iteration and simplifies AI research, as well as Grid View, a web application for monitoring and managing infrastructure. Additionally, it offers Tensorboard for analyzing experiments. The company's solutions are designed to enhance the capabilities of machine learning engineers, data scientists, and AI researchers, allowing them to build advanced AI models and applications with minimal changes to existing code. Grid.ai emerged from the creators of the widely used PyTorch Lightning framework, further solidifying its expertise in high-performance AI research.
Nebulous
Seed Round in 2020
Nebulous, Inc. is a technology company focused on developing blockchain hardware and software infrastructure for the decentralized internet. Founded in 2014 and based in Boston, Massachusetts, the company is known for its flagship product, Sia, a decentralized cloud storage platform that utilizes blockchain technology to create a data storage marketplace. Additionally, Nebulous offers Skynet, a decentralized content delivery network (CDN) and file-sharing platform tailored for developers, along with SiaStream, which provides affordable storage solutions for media files, enabling fast streaming. As a core contributor to the open-source Skynet project, Nebulous plays a significant role in advancing the decentralized web ecosystem.
Rapid Micro Biosystems
Venture Round in 2020
Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.
Atea Pharmaceuticals
Series D in 2020
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on discovering and developing next-generation antiviral therapeutics for severe viral diseases. The company's lead candidate, AT-527, is an antiviral agent currently undergoing phase 3 clinical trials for the treatment of COVID-19, caused by the SARS-CoV-2 virus. Additionally, Atea is advancing several candidates in clinical trials, including AT-787 for hepatitis C and AT-752 for dengue, both in phase 2 trials. The company aims to provide innovative treatments for infections caused by RNA and DNA viruses, improving outcomes for patients suffering from serious viral infections. Atea Pharmaceuticals was incorporated in 2012.
Broadstep Behavorial Health
Private Equity Round in 2020
Broadstep Behavioral Health specializes in providing a comprehensive range of behavioral health and supportive living services for individuals with intellectual and developmental disabilities (I/DD), mental illness, and co-occurring disorders. The organization serves over 1,300 individuals across 86 facilities in states including Wisconsin, North Carolina, New Jersey, Illinois, and South Carolina. Broadstep focuses on delivering physical, emotional, and mental support through various programs, including residential, educational, and vocational services. The aim is to create safe and nurturing environments where individuals feel valued and supported, fostering personal growth and community integration.
BetterCloud
Series F in 2020
BetterCloud specializes in cloud office solutions, serving businesses worldwide. It offers a centralized platform, BetterCloud Discover, providing insights into employee SaaS adoption and streamlining license management across various applications. The company also delivers user lifecycle management, data discovery, security automation, IT automation, and content scanning services for Google Drive, Microsoft SharePoint and OneDrive, Box, Dropbox, and Slack. Its strategic partnership with Dropbox enhances its service offerings.
Affinivax
Series B in 2020
Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, specializing in the development of vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. Founded in 2014, the company aims to enhance the protection against a range of infectious diseases that affect both children and adults globally. MAPS technology allows for the effective binding of protective polysaccharides and proteins within a single vaccine, inducing robust immune responses. Affinivax is advancing vaccine programs targeting significant pathogens, including Streptococcus pneumoniae, which contributes to considerable morbidity and mortality worldwide. The company leverages insights from leading experts in infectious diseases and has secured exclusive intellectual property rights related to its MAPS platform from Boston Children’s Hospital, with notable backing from the Bill & Melinda Gates Foundation.
Mersana Therapeutics
Post in 2020
Mersana Therapeutics is a clinical-stage biopharmaceutical company that develops antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. It leverages proprietary ADC platforms, including Dolaflexin, Dolasynthen, and Immunosynthen, to create a diverse pipeline of product candidates designed to improve therapeutic benefit and address oncology indications underserved by traditional ADCs. The lead candidate XMT-1536 targets NaPi2b and is in Phase I trials for ovarian cancer, non-small cell lung cancer, and other indications. The company also advances additional programs such as Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175, reflecting its focus on next-generation ADCs. Mersana is headquartered in Cambridge, Massachusetts, and was founded in 2005.
Hi Marley
Series A in 2020
Hi Marley is a conversation platform for the insurance industry that combines intelligent messaging with human support to connect customers with insurers. The platform enables insurers to engage policyholders through messaging via its Marley web application, facilitating updates and responses to routine questions. It supports auto, home, and business lines and emphasizes real-time coaching, multilingual support, and automated workflows to enhance customer engagement and operational efficiency. Founded in 2017 and based in Boston, Massachusetts, the company targets insurers seeking to streamline communications and improve satisfaction through a shared messaging experience.
Kymera Therapeutics
Series C in 2020
Kymera Therapeutics is a biotechnology company focused on targeted protein degradation. It employs a proprietary predictive modeling platform to discover novel small molecule therapeutics that selectively degrade disease-causing proteins.
Justworks
Series E in 2020
Justworks, Inc. is a New York-based company founded in 2012 that offers a comprehensive software platform designed to simplify payroll, benefits, human resources, and compliance for small and medium-sized businesses. By serving as a professional employer organization, Justworks enables businesses to bundle essential employment-related functions, allowing them to efficiently manage payroll, employee information, and compliance requirements. The platform also provides access to affordable health insurance and benefits, along with self-service capabilities for businesses to navigate workforce management confidently. Justworks enhances operational efficiency and cost savings through its cloud-based solutions, offering 24/7 support and expertise tailored for modern business needs.
EQRx
Series A in 2020
EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.
Marinus Pharmaceuticals
Post in 2019
Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for rare seizure disorders and neuropsychiatric conditions. The company's lead product candidate, ganaxolone, functions as an allosteric modulator of GABAA receptors and is being developed in both intravenous and oral formulations for use in various patient populations, including adults and children. Ganaxolone is targeted for multiple indications, such as status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment-resistant depression. Marinus Pharmaceuticals emphasizes collaboration with healthcare professionals and partners to enhance patient care and improve the lives of those affected by these conditions. Founded in 2003 and headquartered in Radnor, Pennsylvania, the company is committed to advancing its therapeutic offerings through rigorous scientific research and development.
Grid.ai
Seed Round in 2019
Grid.ai, Inc. is a technology company founded in 2019 and based in New York, New York, that specializes in developing a platform for training artificial intelligence models using cloud-based graphics processing units (GPUs) and tensor processing units (TPUs). The platform provides several tools, including Grid Train, which facilitates research iteration and simplifies AI research, as well as Grid View, a web application for monitoring and managing infrastructure. Additionally, it offers Tensorboard for analyzing experiments. The company's solutions are designed to enhance the capabilities of machine learning engineers, data scientists, and AI researchers, allowing them to build advanced AI models and applications with minimal changes to existing code. Grid.ai emerged from the creators of the widely used PyTorch Lightning framework, further solidifying its expertise in high-performance AI research.
ACV
Series E in 2019
ACV Auctions, Inc. is a wholesale automotive auction company headquartered in Buffalo, New York, founded in 2014. It operates a mobile platform that facilitates online auctions for used-car dealers, allowing them to view, bid on, and purchase car inventory directly from other dealers. The platform provides a digital marketplace that streamlines the buying and selling process, offering real-time alerts for available vehicles and enabling live auction participation. Additionally, ACV Auctions offers a pricing application tailored for franchise dealers, enhancing the auction experience and providing transparent and accurate vehicle information to users.
Ribbon Home
Series B in 2019
Ribbon Home, Inc. is an online real estate platform established in 2017 and headquartered in New York, New York. The company aims to facilitate home ownership by enabling homeowners to purchase new properties before selling their existing ones. By collaborating with local Realtors, Ribbon Home provides clients with the flexibility and time needed to secure the best possible sale price for their current homes. In addition to its real estate services, the company offers financing and leasing options to assist buyers in acquiring properties. Ribbon Home strives to simplify and streamline the home buying process, making it more accessible and less stressful for families looking to transition to new homes.
The Yes
Series A in 2019
The Yes is an artificial intelligence-based shopping platform founded in 2018 and headquartered in Burlingame, California, with additional operations in New York City. The company aims to transform the e-commerce landscape by leveraging AI technology to enhance the online shopping experience. By focusing on innovative solutions, The Yes seeks to attract critical thinkers who can contribute to reimagining the rules of online retail. The platform is dedicated to creating a dynamic and engaging shopping environment for users.
Constellation Pharmaceuticals
Post in 2019
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for unmet medical needs in cancer treatment. The company specializes in the field of epigenetics, aiming to address cancers associated with abnormal gene expression and drug resistance. Its lead product candidates include CPI-0610, which is undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, currently in Phase Ib/II trials for metastatic castration-resistant prostate cancer in conjunction with androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the Phase I dose escalation stage of a Phase I/II trial aimed at treating solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. before rebranding to its current name in March 2008.
Idelic
Series A in 2019
Idelic is a driver management platform based in Pittsburgh, Pennsylvania, founded in 2016. The company specializes in consolidating fleet data systems and automating compliance processes within the transportation industry. Its platform integrates data from various technology sources into a unified system, allowing clients to efficiently manage safety operations and gain predictive insights. By leveraging data organization and artificial intelligence, Idelic aims to enhance driver safety, reduce turnover, and lower insurance costs, ultimately helping to prevent crashes and improve overall fleet performance.
Solid Biosciences
Post in 2019
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.
Nebulous
Seed Round in 2019
Nebulous, Inc. is a technology company focused on developing blockchain hardware and software infrastructure for the decentralized internet. Founded in 2014 and based in Boston, Massachusetts, the company is known for its flagship product, Sia, a decentralized cloud storage platform that utilizes blockchain technology to create a data storage marketplace. Additionally, Nebulous offers Skynet, a decentralized content delivery network (CDN) and file-sharing platform tailored for developers, along with SiaStream, which provides affordable storage solutions for media files, enabling fast streaming. As a core contributor to the open-source Skynet project, Nebulous plays a significant role in advancing the decentralized web ecosystem.
TruVideo
Seed Round in 2019
TruVideo provides a video and text platform for auto repair shops. The core application allows technicians to record videos of vehicle conditions and servicing, narrate issues, and share a link with customers to explain repairs, enhancing transparency. The platform also supports text messaging with customers and includes mobile payment features for approving repairs and completing payments. Serving the automotive service sector, TruVideo helps shops document work, communicate progress, and engage customers throughout the repair process, with capabilities to market vehicles through video content. Founded in 2015 and based in Wellesley, Massachusetts, the company aims to improve customer understanding and trust in vehicle maintenance.
OpenFin
Series C in 2019
OpenFin provides runtime technology solutions for financial desktops. Its platform enables web applications to run outside the browser, generating real-time notifications, communicating with other applications, and meeting strict security standards. Serving financial services industries globally.
Robot Ventures
Seed Round in 2019
Robot Ventures is a New York-based venture capital firm that backs early-stage fintech and blockchain companies, including those in cryptocurrency. It supports founders with ambitious visions and contrarian perspectives, seeking teams that challenge conventional thinking. Founded in 2019, the firm focuses on pre-seed and seed-stage investments, providing capital and guidance to navigate rapidly evolving financial technologies. Robot Ventures targets ventures at the intersection of finance and digital assets with the potential to transform payment systems, capital markets, and related services.
SpringWorks Therapeutics
Series B in 2019
SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying precision medicine to develop medicines for severe rare diseases and cancer. It maintains a differentiated targeted oncology portfolio with lead candidates nirogacestat, a gamma secretase inhibitor, and mirdametinib, a MEK inhibitor, both in late-stage trials; the pipeline also includes BGB-3245, an oral inhibitor of activating BRAF mutations, in Phase I, and several combination programs. The company pursues collaborations with BeiGene, GlaxoSmithKline, and Allogene and has license agreements with Pfizer for nirogacestat and mirdametinib. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks aims to advance potentially registrational studies in rare tumor types and genetically defined cancers through partnerships that expand its portfolio and patient access.
Rent the Runway
Series F in 2019
Rent the Runway is a fashion platform that rents designer dresses, clothing, and accessories for women through its online store and physical locations. Its catalog covers party dresses, gowns, jumpsuits, rompers, outerwear, tops and bottoms, jackets, coats, jewelry, handbags, scarves, hats, and sunglasses. The company operates stores in New York, San Francisco, Santa Monica, and Washington, D.C., and serves customers nationwide online. It supports rental, subscription, and resale options, enabling customers to access a vast closet without ownership. The business emphasizes a cloud-based closet concept and a distinctive reverse logistics network to manage inventory across channels. With partnerships with hundreds of designer brands, Rent the Runway provides hundreds of thousands of pieces for work, weekends, and special occasions. Founded in 2009, the platform aims to disrupt traditional fashion consumption by offering flexible, on-demand access to apparel and accessories.
ACV
Series D in 2018
ACV Auctions, Inc. is a wholesale automotive auction company headquartered in Buffalo, New York, founded in 2014. It operates a mobile platform that facilitates online auctions for used-car dealers, allowing them to view, bid on, and purchase car inventory directly from other dealers. The platform provides a digital marketplace that streamlines the buying and selling process, offering real-time alerts for available vehicles and enabling live auction participation. Additionally, ACV Auctions offers a pricing application tailored for franchise dealers, enhancing the auction experience and providing transparent and accurate vehicle information to users.
Idelic
Seed Round in 2018
Idelic is a driver management platform based in Pittsburgh, Pennsylvania, founded in 2016. The company specializes in consolidating fleet data systems and automating compliance processes within the transportation industry. Its platform integrates data from various technology sources into a unified system, allowing clients to efficiently manage safety operations and gain predictive insights. By leveraging data organization and artificial intelligence, Idelic aims to enhance driver safety, reduce turnover, and lower insurance costs, ultimately helping to prevent crashes and improve overall fleet performance.
Cerevel Therapeutics
Private Equity Round in 2018
Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company is advancing a diverse pipeline that includes five clinical-stage investigational therapies and several preclinical compounds targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Key products under development include CVL-231, a positive allosteric modulator for schizophrenia; CVL-865, which is being tested for drug-resistant focal onset epilepsy and acute anxiety; and Tavapadon, a selective dopamine D1/D5 partial agonist for Parkinson's disease. Cerevel Therapeutics employs a unique approach that leverages expertise in neurocircuitry and receptor selectivity to address unmet medical needs in the field of neuroscience.
Ribbon Home
Series A in 2018
Ribbon Home, Inc. is an online real estate platform established in 2017 and headquartered in New York, New York. The company aims to facilitate home ownership by enabling homeowners to purchase new properties before selling their existing ones. By collaborating with local Realtors, Ribbon Home provides clients with the flexibility and time needed to secure the best possible sale price for their current homes. In addition to its real estate services, the company offers financing and leasing options to assist buyers in acquiring properties. Ribbon Home strives to simplify and streamline the home buying process, making it more accessible and less stressful for families looking to transition to new homes.
Rocket Software
Acquisition in 2018
Founded in 1990, Rocket Software develops enterprise software solutions serving diverse industries worldwide. Its offerings span application lifecycle management, data management, business intelligence, and terminal emulation, among others. The company also provides professional services such as training and consulting.
Unioncrate
Seed Round in 2018
Unioncrate, Inc. is a technology company that specializes in artificial intelligence-driven supply chain management software, aimed at enhancing the operational efficiency of consumer goods companies. Founded in 2016 and headquartered in New York City, with additional offices in Barcelona and Buenos Aires, Unioncrate offers various products including Stargate, which manages sales orders, purchase orders, suppliers, inventory, reporting, trade spending, and EDI, and Almanac, a tool for consumption-driven predictions. The company's platform emphasizes demand planning and utilizes AI to identify demand patterns, automate daily tasks, and improve forecast accuracy, thereby addressing core operational challenges within the supply chain. Unioncrate is dedicated to transforming traditional supply chain practices, enabling clients to reclaim valuable resources that are often lost due to outdated systems.
Flywire
Series D in 2018
Flywire facilitates global payments for educational institutions and their students worldwide. It offers a secure platform supporting diverse payment methods in over 140 currencies across 240 countries.
Centivo
Series A in 2018
Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.
ObserveIT
Series B in 2018
ObserveIT LTD. is a provider of insider threat management software solutions, specializing in detecting, investigating, and preventing insider threats within organizations. Founded in 2006 and headquartered in Boston, Massachusetts, with additional offices in London and Tel Aviv, the company serves a diverse range of industries, including financial services, technology, and manufacturing. Its platform allows organizations to monitor user activity, detect data loss, and respond to incidents more efficiently, significantly reducing investigation times from days to minutes. By offering comprehensive solutions for security teams, ObserveIT aims to enhance the identification of insider threats, streamline investigative processes, and facilitate compliance, ultimately helping organizations safeguard sensitive information and mitigate risks associated with insider actions. ObserveIT operates as a subsidiary of Proofpoint, Inc.
Alice
Seed Round in 2018
Founded in 2015, Alice specializes in AI-driven payroll management software that automates pre-tax spending. It synchronizes with company payroll systems to identify eligible expenses like commuting costs and healthcare, confirming transactions with employees and updating payroll accordingly. The platform also assists HR professionals during employee onboarding.
Rapid Micro Biosystems
Venture Round in 2018
Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.
Penn Foster
Acquisition in 2018
Founded in 1890, Penn Foster is a global leader in online education, offering career-focused degree programs and vocational training. It operates through Penn Foster College, Career School, and High School, providing accredited courses in allied health, business, technology, education, and select trades.
ObserveIT
Series B in 2018
ObserveIT LTD. is a provider of insider threat management software solutions, specializing in detecting, investigating, and preventing insider threats within organizations. Founded in 2006 and headquartered in Boston, Massachusetts, with additional offices in London and Tel Aviv, the company serves a diverse range of industries, including financial services, technology, and manufacturing. Its platform allows organizations to monitor user activity, detect data loss, and respond to incidents more efficiently, significantly reducing investigation times from days to minutes. By offering comprehensive solutions for security teams, ObserveIT aims to enhance the identification of insider threats, streamline investigative processes, and facilitate compliance, ultimately helping organizations safeguard sensitive information and mitigate risks associated with insider actions. ObserveIT operates as a subsidiary of Proofpoint, Inc.
BetterCloud
Series E in 2018
BetterCloud specializes in cloud office solutions, serving businesses worldwide. It offers a centralized platform, BetterCloud Discover, providing insights into employee SaaS adoption and streamlining license management across various applications. The company also delivers user lifecycle management, data discovery, security automation, IT automation, and content scanning services for Google Drive, Microsoft SharePoint and OneDrive, Box, Dropbox, and Slack. Its strategic partnership with Dropbox enhances its service offerings.
World Wide Packaging
Acquisition in 2018
World Wide Packaging LLC is a designer and manufacturer of packaging products tailored for the cosmetic, skincare, and personal care markets. Established in 1980 and headquartered in Florham Park, New Jersey, the company operates an additional facility in Woodland Hills, California. Its extensive product offerings include a variety of packaging solutions such as blush and foundation sticks, cosmetic bottles, metal and plastic lipstick cases, compacts, jars, and tubes for lip gloss, eyeliner, and mascara. Furthermore, World Wide Packaging provides contract manufacturing services that encompass market research, product development, formulation, filling, and secondary packaging solutions. The company is known for its custom-engineered solutions and offers a range of products from basic plastic containers to sophisticated metal packaging, ensuring high quality and competitive pricing for its clients.
Justworks
Series D in 2018
Justworks, Inc. is a New York-based company founded in 2012 that offers a comprehensive software platform designed to simplify payroll, benefits, human resources, and compliance for small and medium-sized businesses. By serving as a professional employer organization, Justworks enables businesses to bundle essential employment-related functions, allowing them to efficiently manage payroll, employee information, and compliance requirements. The platform also provides access to affordable health insurance and benefits, along with self-service capabilities for businesses to navigate workforce management confidently. Justworks enhances operational efficiency and cost savings through its cloud-based solutions, offering 24/7 support and expertise tailored for modern business needs.
Bench
Series B in 2018
Bench Accounting Inc. is a fintech company based in Vancouver, Canada, that specializes in providing online bookkeeping services for small businesses. Founded in 2012, the company combines intuitive software with a dedicated team of professional bookkeepers to automate accounting tasks, allowing clients to manage their finances more efficiently. Bench offers a range of services, including monthly financial statements, year-end financials, and year-round tax support, ensuring that business owners have access to comprehensive financial reporting and expert assistance. With a focus on affordability and convenience, Bench aims to streamline the bookkeeping process, empowering clients to concentrate on growing their businesses. The company has raised significant funding to support its operations and currently employs a workforce dedicated to serving thousands of clients across Canada.
Basis
Initial Coin Offering in 2017
Basis is a company based in Hoboken, New Jersey, founded in 2017. It specializes in developing an algorithmic cryptocurrency protocol designed to regulate supply and maintain purchasing power. The protocol functions similarly to the operations of traditional central banks, which manage fiscal debt to stabilize economic conditions. Basis employs sophisticated algorithms to expand or contract the cryptocurrency's supply in response to market demands, ensuring its value remains stable over time.
SpringWorks Therapeutics
Series A in 2017
SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying precision medicine to develop medicines for severe rare diseases and cancer. It maintains a differentiated targeted oncology portfolio with lead candidates nirogacestat, a gamma secretase inhibitor, and mirdametinib, a MEK inhibitor, both in late-stage trials; the pipeline also includes BGB-3245, an oral inhibitor of activating BRAF mutations, in Phase I, and several combination programs. The company pursues collaborations with BeiGene, GlaxoSmithKline, and Allogene and has license agreements with Pfizer for nirogacestat and mirdametinib. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks aims to advance potentially registrational studies in rare tumor types and genetically defined cancers through partnerships that expand its portfolio and patient access.
mParticle
Series C in 2017
mParticle is a customer data platform provider that helps multi-channel consumer brands collect, unify, and activate data across web, mobile apps, and other touchpoints. The platform enables marketers, developers, product managers, and data scientists to integrate and orchestrate an organization's marketing stack, delivering a single, real-time view of customer data. It collects e-commerce transactions and various API events, supports data across devices and channels, and facilitates audience segmentation and analytics to improve personalization, engagement, and operational efficiency. The company targets industries including retail, financial services, media, travel, gaming, and dining, and supports GDPR compliance. Founded in 2012 and headquartered in New York City, it maintains additional offices in San Francisco, Bellevue, London, and Delray Beach to serve a global client base.
Marinus Pharmaceuticals
Post in 2017
Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for rare seizure disorders and neuropsychiatric conditions. The company's lead product candidate, ganaxolone, functions as an allosteric modulator of GABAA receptors and is being developed in both intravenous and oral formulations for use in various patient populations, including adults and children. Ganaxolone is targeted for multiple indications, such as status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, postpartum depression, and treatment-resistant depression. Marinus Pharmaceuticals emphasizes collaboration with healthcare professionals and partners to enhance patient care and improve the lives of those affected by these conditions. Founded in 2003 and headquartered in Radnor, Pennsylvania, the company is committed to advancing its therapeutic offerings through rigorous scientific research and development.
Replimune Group
Series B in 2017
Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer treatment using its proprietary Immulytic platform. This platform aims to maximize systemic immune activation against tumor antigens through viral-mediated immunogenic tumor cell killing and delivery of optimal immune-activating proteins.
EverTrue
Series C in 2017
EverTrue, Inc. is a software company based in Boston, Massachusetts, that provides a comprehensive platform designed to enhance fundraising efforts at educational institutions. Founded in 2010, the company connects institutional data with insights from various social and demographic sources, including LinkedIn, Facebook, and the U.S. Census. This integration allows advancement offices to better understand and segment their constituents, identify potential donors, and effectively plan events and trips. EverTrue's suite of products includes solutions for alumni community engagement, online giving, relationship management, and volunteer management, serving over 300 institutions. The platform equips fundraising teams with the necessary tools to engage alumni, raise financial support, and track their progress through improved data accessibility and user-friendly functionalities.
GraniteShares
Seed Round in 2017
GraniteShares is an independent ETF company based in New York City. It aims to launch innovative exchange-traded funds, focusing on products that offer new ideas, innovative structures, and low costs.
Flow Commerce
Series A in 2017
Flow Commerce, Inc. is a technology company that specializes in cross-border e-commerce solutions, facilitating international sales for online merchants. Founded in 2015 and headquartered in Hoboken, New Jersey, with an office in Dublin, Ireland, Flow provides a versatile platform that allows e-commerce businesses to easily configure their global supply chain and meet overseas demand. The platform addresses the complexities of international commerce by offering tools for multi-currency pricing, rapid shipping, international payment processing, tax management, and logistics. Flow's solution can be utilized as a comprehensive end-to-end system or as modular components, making it accessible for e-commerce companies of all sizes. By simplifying the buying and selling process across borders, Flow Commerce enhances the overall experience for both merchants and consumers.
Solid Biosciences
Series C in 2017
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.
Dicerna Pharmaceuticals
Post in 2017
Dicerna Pharmaceuticals is a biopharmaceutical company that specializes in the discovery and development of RNA interference (RNAi)-based therapeutics. The company focuses on innovative treatments for rare inherited liver diseases, viral infections, chronic liver diseases, and cardiometabolic conditions. Utilizing its proprietary GalXC RNAi technology platform, Dicerna is advancing several key product candidates, including nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B, and programs targeting genetic liver diseases and cardiovascular conditions. Founded in 2007 and headquartered in Lexington, Massachusetts, Dicerna has established strategic collaborations with major pharmaceutical firms to enhance its research and development efforts.
OpenFin
Series B in 2017
OpenFin provides runtime technology solutions for financial desktops. Its platform enables web applications to run outside the browser, generating real-time notifications, communicating with other applications, and meeting strict security standards. Serving financial services industries globally.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.